|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
41,504,000 |
Market
Cap: |
1.32(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$21.16 - $40.91 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 625 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Collegium Pharmaceutical is a pharmaceutical company. Co.'s portfolio includes: Xtampza ER, Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol. Xtampza ER was approved by the U.S. Food and Drug Administration for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
181,711 |
289,391 |
332,975 |
1,049,160 |
Total Sell Value |
$6,087,407 |
$9,456,240 |
$10,506,887 |
$26,725,036 |
Total People Sold |
4 |
6 |
6 |
7 |
Total Sell Transactions |
5 |
12 |
14 |
44 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2021-01-15 |
4 |
AS |
$22.89 |
$30,261 |
D/D |
(1,322) |
44,395 |
|
-1% |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2021-01-11 |
4 |
D |
$21.18 |
$14,847 |
D/D |
(701) |
45,717 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2021-01-07 |
4 |
AS |
$22.00 |
$352,924 |
D/D |
(16,042) |
111,419 |
|
2% |
|
Fleming Alison B |
Chief Technology Officer |
|
2021-01-07 |
4 |
OE |
$5.73 |
$91,921 |
D/D |
16,042 |
127,461 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2021-01-04 |
4 |
D |
$20.03 |
$21,833 |
D/D |
(1,090) |
184,256 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2020-12-03 |
4 |
AS |
$19.24 |
$114,805 |
D/D |
(5,967) |
111,419 |
|
21% |
|
Ciaffoni Joseph |
President and CEO |
|
2020-11-30 |
4 |
D |
$18.49 |
$86,385 |
D/D |
(4,672) |
185,346 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2020-11-18 |
4 |
OE |
$5.73 |
$91,680 |
D/D |
16,000 |
117,386 |
|
- |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2020-10-15 |
4 |
AS |
$20.82 |
$146,989 |
D/D |
(7,060) |
57,531 |
|
24% |
|
Balice-Gordon Rita J. |
Director |
|
2020-09-24 |
4 |
A |
$0.00 |
$0 |
D/D |
5,027 |
5,027 |
|
- |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2020-09-16 |
4 |
D |
$19.33 |
$14,188 |
D/D |
(734) |
64,591 |
|
- |
|
Heffernan Michael Thomas |
Director |
|
2020-08-11 |
4 |
AS |
$19.13 |
$250,048 |
D/D |
(13,071) |
54,122 |
|
-1% |
|
Brannelly Paul |
Executive Vice President & CFO |
|
2020-08-10 |
4 |
D |
$18.89 |
$28,618 |
D/D |
(1,515) |
173,758 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2020-08-10 |
4 |
D |
$18.89 |
$26,182 |
D/D |
(1,386) |
190,018 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2020-08-10 |
4 |
D |
$18.89 |
$28,618 |
D/D |
(1,515) |
101,386 |
|
- |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2020-07-13 |
4 |
AS |
$17.01 |
$24,307 |
D/D |
(1,429) |
46,418 |
|
13% |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2020-07-10 |
4 |
D |
$16.73 |
$9,938 |
D/D |
(594) |
47,847 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2020-07-01 |
4 |
D |
$17.37 |
$24,214 |
D/D |
(1,394) |
191,404 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2020-06-02 |
4 |
AS |
$20.47 |
$120,058 |
D/D |
(5,861) |
192,798 |
|
7% |
|
Ciaffoni Joseph |
President and CEO |
|
2020-06-01 |
4 |
AS |
$21.53 |
$1,521,709 |
D/D |
(70,676) |
198,659 |
|
7% |
|
Ciaffoni Joseph |
President and CEO |
|
2020-06-01 |
4 |
OE |
$8.22 |
$532,820 |
D/D |
64,820 |
269,335 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2020-06-01 |
4 |
D |
$21.24 |
$99,233 |
D/D |
(4,672) |
204,515 |
|
- |
|
Schroeder Theodore R |
Director |
|
2020-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
4,047 |
11,007 |
|
- |
|
Bohlin Garen G |
Director |
|
2020-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
4,047 |
11,007 |
|
- |
|
Santini Gino |
Director |
|
2020-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
4,047 |
34,195 |
|
- |
|
391 Records found
|
|
Page 7 of 16 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|